Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis
An Observational Study of Novel Survival Prediction Algorithm as Clinical Decision Support for Patients With Non-Small-Cell Lung Cancer (NSCLC) Spinal Metastasis
Sponsor: Ruijin Hospital
A observational or N/A phase clinical study on Non-Small-Cell Lung Cancer Metastatic and Spinal Metastases, this trial is ongoing. The trial is conducted by Ruijin Hospital and has accumulated 8 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Dec 2022 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ruijin Hospital
For direct contact, visit the study record on ClinicalTrials.gov .